The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 02, 2024

Filed:

Mar. 14, 2018
Applicants:

Hyogo College of Medicine, Nishinomiya, JP;

Repertoire Genesis Incorporation, Ibaraki, JP;

Inventors:

Seiji Matsumoto, Nishinomiya, JP;

Ryuji Suzuki, Ibaraki, JP;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/02 (2006.01); G01N 33/574 (2006.01); G16B 25/10 (2019.01); C12Q 1/6886 (2018.01); G16H 20/10 (2018.01); G16H 50/30 (2018.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2809 (2013.01); C07K 16/2815 (2013.01); G01N 33/574 (2013.01); G16B 25/10 (2019.02); G16H 20/10 (2018.01); G16H 50/30 (2018.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); G01N 2800/52 (2013.01);
Abstract

T cell receptor (TCR) diversity of a subject, including TCR diversity in CD8+ T cell subsets, is used as a predictive indicator of responsiveness of the subject to cancer immunotherapy prior to initiation of the immunotherapy. Exemplified immunotherapy comprises administering an immune checkpoint inhibitor to a subject, wherein a TCR diversity value in CD8+ T cell subsets from the subject, such as CD8+ T cell subpopulations defined by differential cell surface marker expression, is higher than a reference value.


Find Patent Forward Citations

Loading…